Skip to content

Health X Platform Limited (HEALTHX)

Small Cap

Pharma stocks · Small cap · NSE

Health X Platform Limited operates in HealthTech, within the Pharma sector. Use the latest filing and company disclosures below to verify its revenue mix and current business drivers.

₹271.1
-8.70 · -3.11%
Market cap ₹879 Cr
Data qualityFresh enough for analysisQuote updated 21 Oct, 03:31 pm IST
Details
Quote21 Oct, 03:31 pm IST
Base fundamentals06 Oct 2026 · screener
Latest result16 Aug, 01:07 am IST
Score22 Oct, 04:30 am IST · v4.3-runtime-valuation
Tags03 May 2026
Coverage13/14 · 93%
Valuation2026-07-20 · Rf 6.8% · Pharma P/E 33.5 (n=187)
Technical timing lens

Trend score and candlestick chart

60Bullish

SMA20 -4.9% / mo · MACD − · near 52W low · sector +5.1pp vs Nifty 500 (3M)

Stock trend: 35
Sector RS: 97
Sector 3M: -0.7% vs Nifty 500 -5.8%
Pharma FPI tailwindNot confirmed

Latest mapped FPI equity flow was not positive. View sector evidence

Technical chart

HEALTHXD candles · FIT view-3.8%
Latest close ₹271.10 on 2026-10-21

Daily history is available from 2026-04-30; the requested 1Y window is partially covered.

Bar
-2.3%
RSI
35
MACD hist
-0.57
52W pos
4%
Visible chart range
Candle interval
2026-10-21O ₹277.60H ₹287.50L ₹267.95C ₹271.10Vol 5,780 sh
₹263.95₹285.93₹307.90₹329.87₹351.8552H52L₹271.102026-032026-06VolRSIMACD2026-042026-062026-082026-092026-11
Up bar
Down bar
EMA 20
EMA 50
Volume + 20D avg
Result date
RSI(14)
MACD / signal
Market context

Relative performance and chart statistics

Adjusted completed-session prices, rebased to 100

HEALTHXNifty PharmaNifty 500
-17%-9%-1%+6%21 Jul2 Sept21 Oct21 Oct 2026HEALTHX -14.8%Nifty Pharma -2.0%Nifty 500 -6.5%
HEALTHX
-14.8%
Nifty 500
-6.5%
Nifty Pharma
-2.0%
Vs Nifty 500
-8.3 pp
Chart stats
21 Oct 2026
From 52W high
-22.1%
₹347.9
52W range position
4%
₹268 - ₹347.9
ATR (14)
5.4%
₹14.5
Volume vs 20D
0.71x
Latest completed session
Avg traded value
₹0.2 Cr
20-session average
20D price channel
₹268 - ₹317
29.6% annualized volatility
Research snapshot

What the evidence says now

Weak fundamentals, management evidence is still limited to a financial-only Trust Lite signal, price trend is neutral, and recent execution is weak.

Suggested next step
Check latest quarters
Result consistency is weak; verify whether the thesis is improving or deteriorating.
U-Score
Legacy · WATCHLIST
36

Fundamental lens: valuation, quality, growth, balance sheet, and cash flow.

Latest result
Bad
2

Revenue +49.7% · PAT -92.5% YoY

Technical
Bullish
60

Price trend and sector-relative-strength timing.

Valuation
Legacy model
—

Legacy margin-of-safety estimate; the revised evidence label remains in shadow validation.

Trust
Limited evidence
67

Financial-only signal; management claim evidence is not sufficient yet.

Financials

Fundamentals, quarterly history, margins, returns and balance-sheet evidence

Latest result

Quarter ended 30 Jun 2026

Bad · 2/100

PAT -93% YoY · margin compression · Rev +50% YoY · +20% QoQ

Filed 30 Jun 2026
Open results browser →
MetricThis quarterYoYQoQ
Revenue₹446.9 Cr+49.7%+19.6%
EBITDA₹-8.4 Cr-238.3%+66.7%
Operating margin-1.9%-391 bps+486 bps
PAT₹2 Cr-92.5%NDF
PAT margin0.5%-846 bps+392 bps

NDF means not disclosed in the current structured filing feed. It is intentionally not treated as zero.

Fundamentals

Valuation

P/E
—
P/B
1.38
EV/EBITDA
—
Market Cap
879.00Cr

Profitability

ROE
0.44%
ROCE
0.03%
ROA
-2.80%
Dividend Y
—

Growth (CAGR)

Revenue 5Y
20.00%
EPS 5Y
18.00%
Revenue 3Y
9.00%
EPS 3Y
27.00%

Balance Sheet

Debt/Equity
0.04
Interest Coverage
-67.00×
Altman Z
4.33
Book Value
201.00

Cash Flow

FCF Yield
11.04%
FCF Positive Y
5/5
OCF
-74.00 Cr
EPS TTM
-6.34

Shareholding

Promoter Hold
74.07%
Promoter Pledge
0.00%
Momentum 52W
20%

Financial History

Updated 22/10/2026

Revenue

₹ Cr
Latest: 1,375+18.6% vs prev
01798Mar 2017: 135Mar 2018: 162Mar 2019: 222Mar 2020: 388Mar 2021: 551Mar 2022: 1,798Mar 2023: 1,060Mar 2024: 1,432Mar 2025: 1,159Mar 2026: 1,375FY17FY18FY19FY20FY21FY22FY23FY24FY25FY26

Net Profit

₹ Cr
Latest: -1.0+99.3% vs prev
-134.00865.0Mar 2017: -29.0Mar 2018: -15.0Mar 2019: -43.0Mar 2020: -52.0Mar 2021: -17.0Mar 2022: 865Mar 2023: -99.0Mar 2024: 6.0Mar 2025: -134Mar 2026: -1.0FY17FY18FY19FY20FY21FY22FY23FY24FY25FY26

Return on Equity

%
Latest: -0.2+99.2% vs prev
-30.10104.6Mar 2017: -14.9%Mar 2018: -8.5%Mar 2019: -30.1%Mar 2020: -24.8%Mar 2021: -8.5%Mar 2022: 105%Mar 2023: -13.1%Mar 2024: 0.8%Mar 2025: -20.0%Mar 2026: -0.2%FY17FY18FY19FY20FY21FY22FY23FY24FY25FY26

Technicals

Trend interpretation, Stage 2, relative strength, volume and indicator evidence

Daily technical trend read

Bearish setup

Trend is weak — long-term trend unclear. RSI 35.

  • SMA20 falling (~5.2% over last month) — short-term momentum negative.
  • RSI(14) at 35 — falling, no extreme reading.
  • MACD below signal, histogram expanding negatively — bearish momentum building.
  • Within 5% of 52-week low — testing support.

Mechanical read from the price + indicator series above. Not a recommendation — technical setups can reverse without warning, especially around earnings and macro events.

Nifty 500 leadership

Relative Strength & Trend Stage

-
RS percentile
Insufficient history
1M return
-8.7%
3M return
-14.8%
6M return
-
1Y return
-
RS 1D
-
RS 20D
-
Sector rank
#1
Industry rank
#14
Stage evidence
  • At least 170 daily sessions are required for the trend-stage read.
50-DMA
price below
200-DMA
unavailable
Sector
leading
Industry
leading
Relative-strength line vs Nifty 500 (base 100)
120 observations
21 Oct 2026Value 99.95-2.20%
9510010611211730 Apr26 Jun23 Aug21 Oct100
RS vs Nifty 500100

Valuation & peers

U-Score 36 · legacy U-Score band WATCHLIST · valuation evidence and comparable companies

36U-SCORE
WATCHLIST

Fundamental score breakdown

U band · WATCHLIST
Valuation5/30
Growth12/25
Quality0/20
Balance Sheet11/15
Cash Flow7/10
Piotroski
4/9 (+1)
Penalties
0
Raw sum
36

Why this score?

Top U-Score contributors and drags from the latest stored fundamentals.

36/100 · legacy band WATCHLIST

Positive drivers

  • FCF yield is supportive at 11.0%.
  • Balance sheet contributes 11/15 to the score.
  • Cash flow contributes 7/10 to the score.

Main drags

  • Quality is weaker at 0/20; verify the latest quarterly trend.
  • Valuation is weaker at 5/30; verify the latest quarterly trend.
  • Growth is weaker at 12/25; verify the latest quarterly trend.
Sector valuation model

Healthcare valuation: PE/EVEBITDA with regulatory and pipeline checks

Healthcare valuation needs both earnings quality and regulatory/pipeline context.

Pharma PE/EVEBITDA
Primary lens
PE and EV/EBITDA adjusted for product mix and R&D/pipeline quality.
Secondary checks
USFDA risk, launch pipeline, margin trend, domestic vs export mix.
Main risk check
Regulatory setbacks or one-off product cycles can distort valuation.
PE
—
PB
1.4
EV/EBITDA
—
ROE
0.4%
ROCE
0.0%
FCF Yield
11.0%
Debt/Equity
0.0
MoS
—
Score movement

Stored run vs live recompute

This shows the stored score trend when snapshots exist, and also compares the latest stored nightly score with a live recompute from current fundamentals and price.

Stored run: 22 Oct 2026
v4.3-runtime-valuation
Final score
36
Previous: 36
Legacy U-Score band
WATCHLIST
Previous: WATCHLIST
Margin of safety
—
No stored baseline yet

Score history

12 stored score snapshots. Latest stored move: +0 points.

22 Oct 2026
v4.3-runtime-valuation
36
36
36
36
36
36
36
36
36
36
36
36

Factor attribution

No pillar movement versus the latest stored run. Historical score trend will appear after snapshot storage is enabled.

Modelled fair value

Graham Number
—
Growth-justified P/E
45.0
Growth-justified Value
—
— MoS
PEG
—

Comparable companies

Peers

Business-comparable peers in Pharma — ranked by industry, sub-sector, theme-tag overlap, market cap, and U-Score similarity. Green cells mark the best available peer metric in this table.

Compare all ↗
Ticker
Name
Why peer
Score
PE
ROE
MoS
Verdict
DHTL
SME
Docmode Health Technologies Ltd.
Healthcare Services
match 150
13
—
-1.6%
—
OVERVALUED
KILITCH
Small
Kilitch Drugs (India) Limited
Healthcare Services
match 138
50
27.5
10.6%
+47%
FAIR VALUE
GAUDIUMIVF
Small
Gaudium IVF and Women Health Limited
Healthcare Services
match 137
56
32.4
24.7%
+40%
FAIR VALUE
ZIMLAB
Small
Zim Laboratories Limited
Healthcare Services
match 137
17
200.0
1.6%
-6300%
OVERVALUED
THEMISMED
Small
Themis Medicare Limited
Healthcare Services
match 137
18
—
0.4%
-2322%
OVERVALUED

Business, management & trust

Growth engines, risks, management commitments and evidence-backed delivery

Business and thesis

Issuer presentation review pending

Health X Platform Limited operates in HealthTech, within the Pharma sector. Use the latest filing and company disclosures below to verify its revenue mix and current business drivers. The structured result feed currently covers the quarter ended 30 Jun 2026. Investor presentations and earnings-call PDFs will be added as issuer-backed evidence before management claims appear here.

Trust Score
67Limited evidence · low confidenceTrust Lite

Trust asks: does management behaviour match later outcomes? Higher is better, but confidence and evidence depth matter as much as the number.

Limited evidence: Claim history is still being built. It ranks around the 52nd percentile of the scored universe and 39th percentile within Pharma. Main check: results consistency is weak at 39/100.

This is a financial-behaviour screen, not a claim-tested management reliability verdict.

Computed 05 Sept 2026
management-trust-v1
77 docs text-extracted · 15 concalls text-extracted
Score band
Limited evidence

Financial behaviour is scored, but management claims do not yet have enough outcome checks.

Relative rank
52nd percentile

overall median 67 · Pharma: 39th pctile, median 70 · Small: 56th pctile, median 66

Evidence depth
Financial-only

77 documents have extracted text, but claim history is not strong enough yet.

Claim delivery
Outcome history still building

0 claims extracted · No contradicted claim yet

How to read this Trust Score

Limited evidence · low confidence
What it measures
Reliability of management and financial delivery, using financial behaviour only.
Confidence
Treat this as an early read until more concalls and outcomes are matched.
Investor use
Acceptable, but check the weakest sub-score before increasing exposure.

Read Trust alongside U-Score, result consistency, and technical trend. A cheap stock with weak Trust needs a larger margin of safety; a high Trust score does not make an expensive stock attractive by itself.

Forensic breakdown

Read low sub-scores as due-diligence warnings, not automatic sell signals.

Promoter
86
strong · holding, pledge, alignment
Cash flow
74
acceptable · profit to cash conversion
Balance sheet
88
strong · leverage and solvency
Discipline
40
weak · capital discipline
Results
39
weak · quarterly consistency

Trust positives

  • ▸Promoter holding is 74.1%.
  • ▸Promoter pledge is zero.
  • ▸FCF yield is 10.2%.
  • ▸5 years of positive FCF.

Trust risks

  • ▸Operating cash flow is negative at ₹-74 Cr.
  • ▸3 latest quarters had PAT decline worse than 25% YoY.
  • ▸ROCE is low at 0%.
  • ▸ROE is low at 0.3%.

Trust Lite uses financial behaviour only. Prefer claim-tested Trust when enough concall claims have later outcomes.

Important announcements & filings

Latest exchange and company disclosures found within the past two years.

12 shown
Annual reportSep 2026

Sep 2026 · Dispatch Of Letter To Shareholders Whose E-Mail Addresses Are Not Registered With The Company Or RTA Or Depository Participants 4 Sep - 37th AGM scheduled for 28 September 2026; annual report link shared with non-registered shareholders.

Source: Bse

Open source ↗
Announcement

Announcement under Regulation 30 (LODR)-Newspaper Publication 5 Sep - Newspaper Publication regarding Notice of 37th Annual General Meeting and e-voting information.

Source: Bse

Open source ↗
Concall transcriptAug 2026

Aug 2026 · Transcript

Source: Bse

Open source ↗
Investor presentationAug 2026

Aug 2026 · PPT

Source: Bse

Open source ↗
Concall transcriptJun 2026

Jun 2026 · Transcript

Source: Bse

Open source ↗
Investor presentationJun 2026

Jun 2026 · PPT

Source: Bse

Open source ↗
Investor presentationJun 2026

Jun 2026 · PPT

Source: Bse

Open source ↗
AnnouncementJun 2026

Jun 2026 · Announcement under Regulation 30 (LODR)-Newspaper Publication 8 Aug - Newspaper Publication of Unaudited Financial Results of the Company for the quarter ended 30th June, 2026

Source: Bse

Open source ↗
Investor presentationJun 2026

Jun 2026 · PPT

Source: Bse

Open source ↗
Announcement

Announcement under Regulation 30 (LODR)-Scheme of Arrangement 10 Jun - Board approved composite scheme: demerger and amalgamations, with 1:3 share ratio and 85,12,168 shares issued.

Source: Bse

Open source ↗
Announcement

Announcement Under Reg 30 (LODR) - Intimation For Change Of Website Of The Company 2 Jun - Company website changed to https://www.healthxplatform.com with immediate effect.

Source: Bse

Open source ↗
Announcement

Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation 2 Jun - Intimation of Schedule of Investors / Analysts Meeting under the SEBI LODR Reg, 2015 and the registration Link

Source: Bse

Open source ↗
Verify on:NSE India ↗
All information is for study purposes only. For investment decisions, consult your financial advisor. See Playbook for methodology.